Partly based on Keio University research, CureApp has developed mobile apps to help treat nicotine addiction and fatty liver inflammation.
CureApp, a Japan-based medical treatment app developer partly based on Keio University research, has raised ¥1.5bn ($14m) in a round featuring the university’s venture capital division, Keio Innovation Initiative (KII), according to The Bridge.
The round also included diversified conglomerate Itochu and its corporate venturing unit Itochu Technology Ventures, life insurance provider Dai-ichi Life and Mitsubishi UFJ Capital, the VC arm of financial services firm Mitsubishi UFJ Financial Group.
Saison Ventures and Mizuho Capital, respective investment vehicles for financial services…